These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19559702)

  • 1. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran A; Andreasson U; Zetterberg H; Westman-Brinkmalm A; Blennow K; Ohrfelt A
    Exp Neurol; 2010 Jun; 223(2):351-8. PubMed ID: 19559702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein.
    Nunan J; Williamson NA; Hill AF; Sernee MF; Masters CL; Small DH
    J Neurosci Res; 2003 Nov; 74(3):378-85. PubMed ID: 14598314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.
    Brinkmalm G; Portelius E; Öhrfelt A; Mattsson N; Persson R; Gustavsson MK; Vite CH; Gobom J; Månsson JE; Nilsson J; Halim A; Larson G; Rüetschi U; Zetterberg H; Blennow K; Brinkmalm A
    J Mass Spectrom; 2012 May; 47(5):591-603. PubMed ID: 22576872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry.
    Gelfanova V; Higgs RE; Dean RA; Holtzman DM; Farlow MR; Siemers ER; Boodhoo A; Qian YW; He X; Jin Z; Fisher DL; Cox KL; Hale JE
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):149-58. PubMed ID: 17584762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of quantitative LC-MS surrogate peptide methodology in the analysis of the amyloid beta peptide (Abeta) biosynthetic intermediate protein APP-betaCTF.
    Cantone JL; Xu-Lin A; Toyn JH; Drexler DM
    J Neurosci Methods; 2009 Jun; 180(2):255-60. PubMed ID: 19464516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
    Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
    Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
    Brinkmalm G; Brinkmalm A; Bourgeois P; Persson R; Hansson O; Portelius E; Mercken M; Andreasson U; Parent S; Lipari F; Ohrfelt A; Bjerke M; Minthon L; Zetterberg H; Blennow K; Nutu M
    Brain Res; 2013 Jun; 1513():117-26. PubMed ID: 23541617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
    Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
    J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
    Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
    Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.
    Du P; Wood KM; Rosner MH; Cunningham D; Tate B; Geoghegan KF
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1144-52. PubMed ID: 17202404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
    Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
    Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Processing of the Alzheimer's disease amyloid precursor protein in Pichia pastoris: immunodetection of alpha-, beta-, and gamma-secretase products.
    Le Brocque D; Henry A; Cappai R; Li QX; Tanner JE; Galatis D; Gray C; Holmes S; Underwood JR; Beyreuther K; Masters CL; Evin G
    Biochemistry; 1998 Oct; 37(42):14958-65. PubMed ID: 9778373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
    Russo C; Salis S; Dolcini V; Venezia V; Song XH; Teller JK; Schettini G
    Neurobiol Dis; 2001 Feb; 8(1):173-80. PubMed ID: 11162251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.
    Portelius E; Westman-Brinkmalm A; Zetterberg H; Blennow K
    J Proteome Res; 2006 Apr; 5(4):1010-6. PubMed ID: 16602710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.